Abstract:You have accessJournal of UrologyBladder Cancer: Basic Research IV1 Apr 2015MP68-20 EXPRESSION OF PDL1 (B7-H1) BEFORE AND AFTER NEOADJUVANT CHEMOTHERAPY IN UROTHELIAL CARCINOMA. Ajjai Alva, Andrew McDaniel, Tianyu Zhan, Hong Xiao, Arul Chinnaiyan, Hui Jiang, Cheryl Lee, and Rohit Mehra Ajjai AlvaAjjai Alva More articles by this author , Andrew McDanielAndrew McDaniel More articles by this author , Tianyu ZhanTianyu Zhan More articles by this author , Hong XiaoHong Xiao More articles by this author , Arul ChinnaiyanArul Chinnaiyan More articles by this author , Hui JiangHui Jiang More articles by this author , Cheryl LeeCheryl Lee More articles by this author , and Rohit MehraRohit Mehra More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2482AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Expression of the co-stimulatory ligand programmed death-ligand 1 - PDL1 (B7-H1) of the PD-PDL immune checkpoint on tumor cells enables evasion of anti-tumor immunity. The PD-PDL checkpoint is a therapeutic target in urothelial carcinoma (UC). We sought to characterize the impact of cytotoxic neoadjuvant chemotherapy (NAC) on PDL1 expression before and after NAC to inform optimal sequencing and combination strategies of immune/cytotoxic therapies. METHODS Immunohistochemical (IHC) staining for PDL1 was performed using a murine anti-B7-H1 monoclonal antibody (clone 5H1) on a tissue microarray with matched pre-NAC T1/T2 transurethral resection (TURBT) samples (T0=2; Tx=1; T1=1; T2=23, T3=11; T4=2) and post-NAC cystectomy samples (pT0N0=15, TisN0=1, T1N0=3, T2N0=6, T3N0=9, T3Nx=1, T4Nx=1, T2N1=1, T3N2, T4N2=1, T3N3=1) from 40 patients (pts) treated from 1999-2011 at the University of Michigan. NAC was cisplatin-based in 13 pts and carboplatin-based in 26 pts. IHC was scored as the product of tumor cell staining intensity (0-3) and percentage of cells positive (0-100). Correlations of T stage at TURBT with the score were analyzed with unpaired t-test and Wilcoxon test. ANOVA analysis and paired t-tests were done to correlate pathologic stage with the score. RESULTS PDL1 expression was significantly higher in post-NAC cystectomy specimens (mean IHC product score = 217.5) compared to the matched pre-NAC TUR specimens (mean IHC product score = 176.6; p = 0.0196 by Student's paired T-test). Among the 21 non-pT0 pts with data at both time-points, PDL1 expression increased after NAC in 16 pts. The percentage of PDL1 positive cells in the residual tissue increased in 15 pts. The PDL1 expression product score in pre-NAC or post-NAC tissue did not correlate with clinical or pathologic stage, or with recurrence-free or overall survival. CONCLUSIONS PDL1 expression in locally advanced UC in pts receiving NAC did not correlate with clinical outcomes in our small cohort. However, the expression of PDL1 in post-NAC tissue was elevated compared to pre-NAC. The increased PDL1 expression following NAC informs rational combinations of anti-PD1 immunotherapies with cytotoxic chemotherapy, and their sequencing in UC. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e866 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ajjai Alva More articles by this author Andrew McDaniel More articles by this author Tianyu Zhan More articles by this author Hong Xiao More articles by this author Arul Chinnaiyan More articles by this author Hui Jiang More articles by this author Cheryl Lee More articles by this author Rohit Mehra More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...